UPSHER-SMITH PREVIEWS EXPANSION OF ITS RARE DISEASE PORTFOLIO AT 2024 AAN ANNUAL MEETING

Discover the Company's Promise of Support™ Program at Booth #818

MAPLE GROVE, Minn., April 12, 2024 /PRNewswire/ -- Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced that it will be participating in the 2024 American Academy of Neurology (AAN) Annual Meeting in Denver, from April 13 to 18, 2024. Representatives from Upsher-Smith will be on hand at Booth #818 to showcase its expanding portfolio of medications backed by the Promise of Support™ Program, including the VIGADRONE ^® (vigabatrin) product family and TORPENZ™ (everolimus) Tablets slated for availability in mid-2024.

Since the successful launch of VIGADRONE ^® (vigabatrin) for Oral Solution, USP 500 mg to the specialty pharmacy channel in 2018, Upsher-Smith has broadened its offerings to include VIGADRONE ^® (vigabatrin) Tablets, USP 500 mg. TORPENZ™ Tablets, a branded-generic everolimus tablet, will soon be available to prescribers and patients.

Central to Upsher-Smith's commitment to rare disease communities is its Promise of Support™ Program, ensuring comprehensive assistance for patients, caregivers, and healthcare providers throughout the treatment journey. For more than five years, the program has offered resources for uninterrupted medication supply, prior authorization support, copay and patient assistance, patient education materials, collaboration with a leading specialty pharmacy partner, and streamlined prescribing and enrollment procedures.

Rich Fisher, President and COO of Upsher-Smith emphasized the company's dedication to improving access and affordability to its products while prioritizing unparalleled service and support. "We understand the challenges faced by families battling rare diseases, and our team is steadfast in delivering solutions that ease some of the burden for patients and their families. We eagerly anticipate previewing our new everolimus option at this year's American Academy of Neurology Annual Meeting and engaging attendees in discussions about the benefits of our Promise of Support™ Program."

To learn more about Upsher-Smith's Promise of Support™ Program for the VIGADRONE ^® family of products, visit VIGADRONE.com, and to stay updated on TORPENZ™ (everolimus) Tablets, visit www.torpenz.com/availability.

Please see Important Safety Information, including Boxed Warning for Risk of Permanent Vision Loss at the end of this communication.

VIGADRONE ^® (vigabatrin) is a prescription medicine used to treat:

• Infantile Spasms (IS) in patients 1  month to 2  years of age, if you and your healthcare provider decide the possible benefits of taking VIGADRONE  are more important than the possible risk of vision loss.
• Refractory Complex Partial Seizures (CPS) in adults and children 2 years and older with refractory complex partial seizures (CPS) along with other treatments if:
  • The CPS do not respond well enough to several other treatments, and
  • You and your healthcare provider decide the possible benefit of taking VIGADRONE is more important than the risk of vision loss.

VIGADRONE should not be the first medicine used to treat CPS.

WHAT IMPORTANT SAFETY INFORMATION SHOULD I KNOW ABOUT VIGADRONE ^® (vigabatrin)?

• Because VIGADRONE  might cause permanent vision loss, it is available to healthcare providers and patients only under a special program called the Vigabatrin Risk Evaluation and Mitigation Strategy (REMS) Program. Your healthcare provider will explain the details of this Program to you.
  
  
• VIGADRONE  can damage the vision of anyone who takes it. Some people can have severe loss, particularly to their ability to see to the side when looking straight ahead (peripheral vision). With severe vision loss, you may only be able to see things straight in front of you (sometimes called "tunnel vision"). You may also have blurry vision. If this happens, it will not get better.
  
  
• Tell your healthcare provider right away if you (or your child): might not be seeing as well as before starting VIGADRONE; start to trip, bump into things, or are more clumsy than usual; are surprised by people or things coming in front of you that seem to come out of nowhere; or if your baby is acting differently than normal. These changes can mean that vision damage has occurred.
  
  
• Regular vision testing is recommended.  It is recommended that your healthcare provider test your (or your child's) vision before or within 4 weeks after starting VIGADRONE, and at least every 3 months during treatment until VIGADRONE  is stopped. It is also recommended that vision be tested about 3 to 6 months after VIGADRONE  is stopped. It is difficult to test vision in babies, but to the extent possible, all patients should have their vision tested. Your healthcare provider will determine if testing can be done. Regular vision testing is important because damage can happen before any changes are noticed.
  
  
• Vision tests cannot prevent the vision damage  that can happen with VIGADRONE, but they do allow VIGADRONE  to be stopped if vision has gotten worse, which usually will lessen further damage. Even these regular vision tests may not show vision damage before it is serious and permanent. Parents, caregivers, and healthcare providers may not recognize the symptoms, or find vision loss in patients, until it is severe.
  
  
• If you do not have these vision tests regularly, your healthcare provider may stop prescribing  VIGADRONE  for you (or your child). Some people are not able to complete vision testing. If vision testing cannot be done, your healthcare provider may continue prescribing VIGADRONE, but will not be able to watch for any vision loss.
  
  
• Magnetic resonance imaging (MRI) changes in patients with infantile spasms (IS). Brain pictures taken by MRI show changes in some patients after they are given VIGADRONE. It is not known if these changes are harmful.
  
  
• A type of swelling in the brain called  intramyelinic edema (IME) has been seen  in autopsy examination of patients treated with vigabatrin.
  
  
• Risk of suicidal thoughts or actions.  Like other antiepileptic drugs, VIGADRONE may cause suicidal thoughts and actions in some people (about 1 in 500 people). Call a healthcare provider right away if you (or your child) have any symptoms, especially sudden changes in mood, behaviors, thoughts or feelings, and especially if they are new, worse, or worry you.
  
  
• Do not stop  VIGADRONE without first talking to a healthcare provider. Stopping VIGADRONE suddenly can cause seizures that will not stop.

VIGADRONE can cause serious side effects such as low red blood cell counts (anemia), sleepiness and tiredness, nerve problems, weight gain, and swelling. Because  VIGADRONE causes sleepiness and tiredness, do not drive, operate machinery, or perform any hazardous task, unless it is decided that these things can be done safely. VIGADRONE may make certain types of seizures worse. Tell your healthcare provider right away if seizures get worse.

Before starting VIGADRONE, tell your doctor about all of your (or your child's) medical conditions  including depression, mood problems, suicidal thoughts or behavior, any allergic reaction to VIGADRONE, vision problems, kidney problems, low red blood cell counts (anemia), and any nervous or mental illnesses. Tell your doctor about all the medicines you (or your child) take.

If you are breastfeeding or plan to breastfeed, VIGADRONE can pass into breast milk and may harm your baby. Breastfeeding is not recommended.

If you are pregnant or plan to become pregnant, VIGADRONE  can cause harm to your unborn baby. You and your healthcare provider will have to decide if you should take VIGADRONE while you are pregnant.

The most common side effects of VIGADRONE  in adults include:  blurred vision, sleepiness, dizziness, problems walking or feeling uncoordinated, shaking (tremor) and tiredness.

The most common side effect of VIGADRONE  in children 3 to 16 years of age  is weight gain. Also expect side effects like those seen in adults.

The most common side effects of VIGADRONE  in babies include:  sleepiness (sleepy babies may have a harder time suckling and feeding or may be irritable), swelling in the bronchial tubes (bronchitis), ear infection and irritability.

Tell your healthcare provider if you or your child have any side effect that bothers you or that does not go away.  

This is the most important information to know about VIGADRONE, but it is not all the safety information. For more information, ask your healthcare provider or pharmacist, or please see the VIGADRONE Medication Guide,  full Prescribing Information  including Boxed Warning for risk of permanent vision loss, and  Instructions for Use. You can also visit vigadrone.com, upsher-smith.com or call 1-888-650-3789.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit  www.fda.gov/medwatch, or call  1-800-332-1088.

About Upsher-Smith

Upsher-Smith Laboratories, LLC, now a member of Bora Group, is a trusted U.S. pharmaceutical company that strives to improve the health and lives of patients through an unwavering commitment to high-quality products and sustainable growth. We bring generics and brands to a wide array of customers, always backed by our attentive level of service, strong industry relationships, and dedication to uninterrupted supply. For more information, visit www.upsher-smith.com.

About Bora

Founded in 2007,  Bora Pharmaceutical Co., Ltd. ("Bora" or "the Company", 6472.TW) now is the largest pharmaceutical manufacturer in Taiwan with well-connected global distribution to supply more than 100 countries around the world. Headquartered in Taiwan, Bora has dedicated itself to becoming a global leader in pharmaceutical manufacturing by offering its clients the best quality, efficiency and reliability.

VIGADRONE, TORPENZ, and PROMISE OF SUPPORT are trademarks of Upsher-Smith Laboratories, LLC.